Cargando…
Improving Antibacterial Activity of a HtrA Protease Inhibitor JO146 against Helicobacter pylori: A Novel Approach Using Microfluidics-Engineered PLGA Nanoparticles
Nanoparticle drug delivery systems have emerged as a promising strategy for overcoming limitations of antimicrobial drugs such as stability, bioavailability, and insufficient exposure to the hard-to-reach bacterial drug targets. Although size is a vital colloidal feature of nanoparticles that govern...
Autores principales: | Hwang, Jimin, Mros, Sonya, Gamble, Allan B., Tyndall, Joel D. A., McDowell, Arlene |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8875321/ https://www.ncbi.nlm.nih.gov/pubmed/35214080 http://dx.doi.org/10.3390/pharmaceutics14020348 |
Ejemplares similares
-
Establishment of serine protease htrA mutants in Helicobacter pylori is associated with secA mutations
por: Zawilak-Pawlik, Anna, et al.
Publicado: (2019) -
Trimer stability of Helicobacter pylori HtrA is regulated by a natural mutation in the protease domain
por: Zarzecka, Urszula, et al.
Publicado: (2023) -
Characterisation of worldwide Helicobacter pylori strains reveals genetic conservation and essentiality of serine protease HtrA
por: Tegtmeyer, Nicole, et al.
Publicado: (2015) -
Amino-Terminal Processing of Helicobacter pylori Serine Protease HtrA: Role in Oligomerization and Activity Regulation
por: Albrecht, Nicole, et al.
Publicado: (2018) -
Calcium binding protects E-cadherin from cleavage by Helicobacter pylori HtrA
por: Schmidt, Thomas P., et al.
Publicado: (2016)